ProKidney jumps on positive mid-stage data for therapy

Prokidney

10/06/2024 12:19

** Shares of cell therapy developer ProKidney  PROK.O  rise
~19.8% to $3.82 in premarket trade
    ** Company says its cell therapy, rilparencel, showed
stabilization of kidney function for 18 months in patients with
chronic kidney disease, a situation when kidneys are damaged and
can't filter blood the usual way
    ** Up to last close, stock up 79.2% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))